Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: Pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro

Platelets

Volumn 14, Issue 7-8, 2003, Pages 445-462

  Maayani, Saul ^a   Schwarz, Todd E ^a   Patel, Nayana D ^a   Craddock Royal, Barbara D ^a   Tagliente, Thomas M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ALPHA 2A ADRENERGIC RECEPTOR; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; MEMBRANE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PURINE P2Y RECEPTOR; PURINE RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; RECEPTOR; RECEPTOR EP 3; UNCLASSIFIED DRUG; WORTMANNIN;

ARTICLE; BINDING AFFINITY; CELL KINETICS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DESENSITIZATION; DRUG RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; MODULATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEADY STATE; THROMBOCYTE AGGREGATION; THROMBOCYTE SHAPE; TURBIDIMETRY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ADENYLATE CYCLASE; ALGORITHMS; ANDROSTADIENES; BLOOD PLATELETS; CELL SIZE; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPINEPHRINE; HUMANS; KETANSERIN; KINETICS; MEMBRANE PROTEINS; NEPHELOMETRY AND TURBIDIMETRY; PHENTOLAMINE; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROPRANOLOL; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, PURINERGIC P2; SIGNAL TRANSDUCTION; THIONUCLEOTIDES;

EID: 0346672400     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537100310001612399     Document Type: Article

References (100)

1. Abrams C S, Brass L F. Platelet signal transduction. In: Colman R W, Hirsh J, Marder V J, Clows A W, George J N, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Baltimore, MD: Lippincott Williams & Wilkins, 2001; 541-59.
2. Hellem A J. The addhesiveness of human bloodplatelets in vitro. Scand J Clin Lab Invest 1960; 12: 1-117.
3. Gaarder A, Jonsen J, Laland S, Hellem A, Owen P A. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-2.
4. Born G V R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-9.
5. Storey R F, Sanderson H M, White A E, May J A, Cameron K E, Heptinstall S. The central role of the P-2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925-34.
6. Storey R F, Newby L J, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001; 12: 443-7.
7. Holmsen H, Weiss H J. Hereditary defect in the platelet release reaction caused by a deficiency in the storage pool of platelet adenine nucleotides. Br J Haematol 1970; 19: 643-9.
8. Holmsen H, Weiss H J. Secretable storage pools in platelets. Annu Rev Med 1979; 30: 119-34.
9. Savi P, Herbert J M. Pharmacology of ticlopidine and clopidogrel. Haematologica 2000; 85: 73-7.
10. Ingall A H, Dixon J, Bailey A, Coombs M E, Cox D, McInally J I, et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999; 42: 213-20.
11. Humphries R G. Pharmacology of AR-C69932MX and related compounds: from pharmacological tools to clinical trials. Haematologica 2000; 85: 66-72.
12. Curtin R, Cox D, Fitzgerald D. Clopidogrel and Ticlopidine. In: Michelson A D, ed. Platelets. New York: Academic Press, 2002; 787-801.
13. Gachet C, Cazenave J-P. Platelet receptors: ADP. In: Gresele P, Clive P, Fuster V, Vermylen J, eds. Platelets in Thrombotic and Non-Thrombotic Disorders. Cambridge: Cambridge University Press, 2002; 127-39.
14. Keularts I M, van Gorp R M, Feijge M A, Vuist W M, Heemskerk J W. Alpha(2A)-adrenergic receptor stimulation potentiates calcium release in platelets by modulating cAMP levels. J Biol Chem 2000; 275: 1763-72.
15. Selheim F, Idsoe R, Fukami M H, Holmsen H, Vassbotn F S. Formation of PI 3-kinase products in platelets by thrombin, but not collagen, is dependent on synergistic autocrine stimulation, particularly through secreted ADP. Biochem Biophys Res Commun 1999; 263: 780-5.
16. Payrastre B, Gratacap M-P, Trumel C, Missy K, Chap H, Gachet C, et al. ADP: an important cofactor of PI 3-kinase activation in human blood platelets. Haematologica 2000; 85: 32-6.
17. Payrastre B, Missy K, Trumel C, Bodin S, Plantavid M, Chap H. The integrin alpha IIb/beta 3 in human platelet signal transduction. Biochem Pharmacol 2000; 60: 1069-74.
18. Jin J, Kunapuli S P. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95: 8070-4.
19. Jarvis G E, Humphries R G, Robertson M J, Leff P. ADP can induce aggregation of human platelets via both P2Y(1) and P-2T receptors. Br J Pharmacol 2000; 129: 275-82.
20. Maayani S, Patel N D, Craddock-Royal B, Schwarz T E, Tagliente T M. Concurrent responses elicited by isolated activation of platelet Gq-coupled receptors, in vitro: a novel approach for their separation and analysis. Platelets 2003; 14: 89-102.
21. Maayani S, Tagliente T M, Schwarz T, Martinelli G, Martinez R, Shore-Lesserson L. The balance of concurrent aggregation and deaggregation processes in platelets is linked to differential occupancy of ADP receptor subtypes. Platelets 2001; 12: 83-93.
22. Maayani S, Tagliente T M, Schwarz T, Craddock-Royal B, Alcala C, Marrero G, et al. Deaggregation is an integral component of the response of platelets to ADP in vitro: kinetic studies of literature and original data. Platelets 2001; 12: 279-91.
23. Maayani S, Schwarz T, Craddock-Royal B, Tagliente T M. Activation of the alpha(2A)-adrenoceptor mediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro. Platelets 2001; 12: 359-75.
24. Maayani S, Schwarz T, Martinez R, Tagliente T M. Activation of Gi-coupled receptors releases a tonic state of inhibited platelet aggregation. Platelets 2001; 12: 94-8.
25. Ozaki Y, Satoh K, Yatomi Y, Yamamoto T, Shirasawa Y, Kume S. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem 1994; 218: 284-94.
26. Yamamoto T, Egawa Y, Shirasawa Y, Ozaki Y, Sato K, Yatomi Y, et al. A laser light scattering in situ system for counting aggregates in blood platelet. Meas Sci Technol 1995; 6: 174-80.
27. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000; 111: 733-44.
28. Ryningen A, Holmsen H. Role of autocrine stimulation for the effects of cyclic AMP on protein and lipid phosphorylation in platelets activated by particles. FEBS Lett 1998; 436: 335-8.
29. Ryningen A, Jensen B O, Holmsen H. Role of autocrine stimulation on the effects of cyclic AMP on protein and lipid phosphorylation in collagen-activated and thrombin-activated platelets. Eur J Biochem 1999; 260: 87-96.
30. Macfarlane D E, Srivastava P C, Mills D C. 2-Methylthioadenosine[beta- 32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J Clin Invest 1983; 71: 420-8.
31. De Clerck F, Xhonneux B, Leysen J, Janssen P A. Evidence for functional 5-HT2 receptor sites on human blood platelets. Biochem Pharmacol 1984; 33: 2807-11.
32. Fukami M H, Holmse H, Kowalska M A, Niewiarowski S. Platelet secretion. In: Colman R W, Hirsh J, Marder V J, Clowes A W, George J N, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th edn. Baltimore, MD: Lippincott Williams and Wilkins, 2001; 561-73.
33. Hause L L, Retzinger G S, Megan P A. A compartmental model of platelet aggregation in vitro: the kinetics of single platelets. Thromb Res 1989; 56: 133-46.
34. Wachsman D E, Kavaler I P, Sugar I P, Schachter E N, Gonsiorek W, Maayani S. Kinetic studies of desensitization and resensitization of the relaxation response to beta-2 adrenoceptor agonists in isolated guinea pig trachea. J Pharmacol Exp Ther 1997; 280: 332-45.
35. Gaddum J H. Biological aspects: the antagonism of drugs. Trans Faraday Soc 1943; 39: 323-33.
36. Gaddum J H. Theories of drug antagonism. Pharmacol Rev 1957; 9: 211-8.
37. Cheng Y, Prusoff W H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-108.
38. Born V R, Cross M J. The aggregation of blood platelets. J Physiol 1963; 168: 178-95.
39. Ashby B, Colman R W, Daniel J L, Kunapuli S P. Platelet stimulatory and inhibitory receptors. In: Colman R W, Hirsh J, Marder V I, Clows A W, George J N, eds. Hemostasis and Thrombosis; Basic Principles and Clinical Practice. Baltimore, MD: Lippincott Williams & Wilkins, 2001; 505-20.
40. Macfarlane D E, Mills D C, Srivastava P C. Binding of 2-azidoadenosine [beta-32P]diphosphate to the receptor on intact human blood platelets which inhibits adenylate cyclase. Biochemistry 1982; 21: 544-9.
41. Schachter J B, Li Q, Boyer J L, Nicholas R A, Harden T K. Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinoceptor. Br J Pharmacol 1996; 118: 167-73.
42. Fagura M S, Dainty I A, McKay G D, Kirk I P, Humphries R G, Robertson M J, et al. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors. Br J Pharmacol 1998; 124: 157-64.
43. Leon C, Hechler B, Vial C. Leray C. Cazenave J P, Gachet C. The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 1997; 403: 26-30.
44. Boyer J L, Romero-Avila T, Schachter J B, Harden T K. Identification of competitive antagonists of the P2Y1 receptor. Mol Pharmacol 1996; 50: 1323-9.
45. Jantzen H-M, Gousset L, Bhaskar V, Vincent D, Tai A, Reynolds E E, et al. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation. Thromb Haemost 1999; 81: 111-7.
46. Anfossi G, Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest 1996; 26: 353-70.
47. Matthews J S, Jones R L. Potentiation of aggregation and inhibition of adenylate-cyclase in human platelets by prostaglandin-E analogs. Br J Pharmacol 1993; 108: 363-9.
48. Armstrong R A. Platelet prostanoid receptors. Pharmacol Ther 1996; 72: 171-91.
49. Fabre J-E, Nguyen M, Athirakul K, Coggins K, McNeish J D, Austin S, et al. Activation of the murine EP3 receptor for PGE(2) inhibits cAMP production and promotes platelet aggregation. J Clin Invest 2001; 107: 603-10.
50. Michal F, Maguire M H, Gough G. 2-Methylthioadenosine-5′-phosphate: a specific inhibitor of platelet aggregation. Nature 1969; 222: 1073-4.
51. Hollopeter G, Jantzen H-M, Vincent D, Li G, England L, Ramakrishman V. et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-7.
52. Boyer J L, Schachter J B, Sromek S M, Palmer R K, Jacobson K A, Nicholas R A. et al. Avian and human homologues of the P2Y(1) receptor: pharmacological, signaling, and molecular properties. Drug Dev Res 1996; 39: 253-61.
53. Woulfe D, Yang J, Prevost N, O'Brien P J, Brass L F. Signal transduction during the initiation, extension and perpetuation of platelet plug formation. In: Michelson A D, ed. Platelets. New York: Academic Press, 2002; 197-214.
54. Trumel C, Payrastre B, Plantavid M, Hechler B, Viala C, Presek P, et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94: 4156-65.
55. Wilde J I, Retzer M, Siess W, Watson S P. ADP-induced platelet shape change: an investigation of the signalling pathways involved and their dependence on the method of platelet preparation. Platelets 2000; 11: 286-95.
56. Katsel P L, Tagliente T M, Schwartz T E, Craddock-Royal B D, Patel N D, Maayani S. Molecular and biochemical evidence for the presence of type III adenylyl cyclase in human platelets. Platelets 2003; 14: 21-33.
57. Haslam R J, Lynham J A. Relationship between phosphorylation of blood platelet proteins and secretion of platelet granule constituents. I. Effects of different aggregating agents. Biochem Biophys Res Commun 1977; 77: 714-22.
58. 2) receptor; pharmacological and kinetic studies in vitro. Platelets 2003; 14(6): 359-74.
59. Jin J G, Daniel J L, Kunapuli S P. Molecular basis for ADP-induced platelet activation II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273: 2030-4.
60. Waldo G L, Corbitt J, Boyer J L, Ravi G, Kim H S, Ji X D, et al. Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol 2002; 62: 1249-57.
61. Savi P, Pflieger A M, Herbert J M. cAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coagul Fibrinolysis 1996: 7: 249-52.
62. Baurand A, Eckly A, Bari N, Leon C, Hechler B, Cazenave J-P, et al. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y(1) and P2cyc receptors. Thromb Haemost 2000; 84: 484-91.
63. Ardlie N G, Perry D W, Packham M A, Mustard J F. Influence of apyrase on stability of suspensions of washed rabbit platelets. Proc Soc Exp Biol Med 1971; 136: 1021-3.
64. Holme S, Real C, Holmsen H. ADP-induced refractory state of platelets in vitro. I. Methodological studies on aggregation in platelet rich plasma. Scand J Haematol 1975; 15: 96-103.
65. Holme S, Sixma J J, Wester J, Holmsen H. ADP-induced refractory state of platelets in vitro. II. Functional and ultra studies on gel filtered platelets. Scand J Haematol 1977; 18: 267-78.
66. Premont R T, Inglese J, Lefkowitz R J. Protein kinases that phosphorylate activated G protein-coupled receptors. FASEB J 1995; 9: 175-82.
67. Goodman O B Jr, Krupnick J G, Santini F, Gurevich V V, Penn R B, Gagnon A W, et al. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 1996; 383: 447-50.
68. Ferguson S S, Zhang J, Barak L S, Caron M G. G-protein-coupled receptor kinases and arrestins: regulators of G-protein-coupled receptor sequestration. Biochem Soc Trans 1996; 24: 953-9.
69. Ferguson S S, Barak L S, Zhang J, Caron M G. G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. Can J Physiol Pharmacol 1996; 74: 1095-110.
70. Kenakin T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 1995; 16: 232-8.
71. Offermanns S. The role of heterotrimeric G proteins in platelet activation. Biol Chem 2000; 381: 389-96.
72. Berg K A, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke W P. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 1998; 54: 94-104.
73. Berg K A, Maayani S, Clarke W P. Interactions between effectors linked to serotonin receptors. Ann NY Acad Sci 1998; 861: 111-20.
74. Berg K A, Maayani S, Goldfarb J, Clarke W P. Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists. Ann NY Acad Sci 1998; 861: 104-10.
75. Stout B D, Clarke W P, Berg K A. Rapid desensitization of the serotonin(2C) receptor system: effector pathway and agonist dependence. J Pharmacol Exp Ther 2002; 302: 957-62.
76. Chikumi H, Vazquez-Prado J, Servitja J M, Miyazaki H, Gutkind J S. Potent activation of RhoA by Galpha q and Gq-coupled receptors. J Biol Chem 2002; 277: 27130-4.
77. Hirata T, Ushikubi F, Kakizuka A, Okuma M, Narumiya S. Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 1996; 97: 949-56.
78. Habib A, FitzGerald G A, Maclouf J. Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem 1999; 274: 2645-51.
79. Weber A-A, Hohlfeld T, Schror K. cAMP is an important messenger for ADP-induced platelet aggregation. Platelet 1999; 10: 238-41.
80. Kurrasch-Orbaugh D M, Watts V J, Barker E L, Nichols D E. Serotonin 5-hydroxytryptamine(2A) receptor-coupled phospholipase C and phospholipase A(2) signaling pathways have different receptor reserves. J Pharmacol Exp Ther 2003; 304: 229-37.
81. Hall R A, Premont R T, Lefkowitz R J. Heptahelical receptor signaling: beyond the G protein paradigm. J Cell Biol 1999; 145: 927-32.
82. Hall R A, Spurney R F, Premont R T, Rahman N, Blitzer J T, Pitcher J A, et al. G protein-coupled receptor kinase 6A phosphorylates the Na(+)/H(+) exchanger regulatory factor via a PDZ domain-mediated interaction. J Biol Chem 1999; 274: 24328-34.
83. Marinissen M J, Gutkind J S. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 2001; 22: 368-76.
84. Milligan G, White J H. Protein-protein interactions at G-protein-coupled receptors. Trends Pharmacol Sci 2001; 22: 513-8.
85. Selheim F, Froyset A K, Strand I, Vassbotn F S, Holmsen H. Adrenaline potentiates PI 3-kinase in platelets stimulated with thrombin and SFRLLN: role of secreted ADP. FEBS Lett 2000; 485: 62-6.
86. Kovacsovics T J, Bachelot C, Toker A, Vlahos C J, Duckworth B, Cantley L C, et al. Phosphoinositide 3-kinase inhibition spares actin assembly in activating platelets but reverses platelet aggregation. J Biol Chem 1995; 270: 11358-66.
87. Zhang J, Banfic H, Straforini F, Tosi L, Volinia S, Rittenhouse S E. A type II phosphoinositide 3-kinase is stimulated via activated integrin in platelets. A source of phosphatidylinositol 3-phosphate. J Biol Chem 1998; 273: 14081-4.
88. Heptinstall S, May J A, Glenn J R, Sanderson H M, Dickinson J P, Wilcox R G. Effects of ticlopidine administered to healthy volunteers on platelets function in whole blood. Thromb Haemost 1995; 74: 1310-5.
89. Mateos-Trigos G, Evans R J, Heath M F. Effects of a P2Y(12) receptor antagonist on the response of equine platelets to ADP. Comparison with human platelets. Res Vet Sci 2002; 73: 171-5.
90. Cattaneo M, Canciani M T, Lecchi A, Kinlough-Rathbone R L, Packham M A, Mannucci P M, et al. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood 1990; 75: 1081-6.
91. Kinlough-Rathbone R L, Packham M A, Perry D W, Mustard J F, Cattaneo M. Lack of stability of aggregates after thrombin-induced reaggregation of thrombin-degranulated platelets. Thromb Haemost 1992; 67: 453-7.
92. Lau L F, Pumiglia K, Cote Y P, Feinstein M B. Thrombin-receptor agonist peptides, in contrast to thrombin itself, are not full agonists for activation and signal transduction in human platelets in the absence of platelet-derived secondary mediators. Biochem J 1994; 303: 391-400.
93. Cattaneo M, Zighetti M L, Lombardi R, Martinez C, Lecchi A, Conley P B, et al. Molecular bases of defective signal transduction in the platelet P2Y(12) receptor of a patient with congenital bleeding. Proc Natl Acad Sci USA 2003; 100: 1978-83.
94. Cattaneo M, Lecchi A, Randi A M, McGregor J L, Mannucci P M. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 1992; 80: 2787-96.
95. Nurden P, Savi P, Heilmann E, Bihour C, Herbert J-M. Maffrand J-P, et al. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. J Clin Invest 1995; 95: 1612-22.
96. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19: 2281-5.
97. Leon C, Vial C, Gachet C, Ohlmann P, Hechler B, Cazenave J-P, et al. The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation. Thromb Haemost 1999; 81: 775-81.
98. Ma H, Kara A, Xiao C Y, Okada Y, Takahata O, Nakaya K, et al. Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E receptor subtype EP(3). Circulation 2001; 104: 1176-80.
99. Rao A K, Willis J, Kowalska M A, Wachtfogel Y T, Colman R W. Differential requirements for platelet aggregation and inhibition of adenylate cyclase by epinephrine. Studies of a familial platelet alpha 2-adrenergic receptor defect. Blood 1988; 71: 494-501.
100. Tamponi G, Pannocchia A, Arduino C, Bazzan M, Della Dora N, Schinco P, et al. Congenital deficiency of alpha-2-adrenoceptors on human platelets: description of two cases. Thromb Haemost 1987; 58: 1012-6.